Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.
about
What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutationsDiminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.Genome-wide association study identifies common and low-frequency variants at the AMH gene locus that strongly predict serum AMH levels in males.Anti-Müllerian hormone serum level and other markers associated with pregnancy outcome in oocyte donation.Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA.Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone.Prediction of metaphase II oocytes according to different serum Anti-Müllerian hormone (AMH) levels in antagonist ICSI cycles.Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing.Trends in 'poor responder' research: lessons learned from RCTs in assisted conception.Retrospective cohort study: AMH is the best ovarian reserve markers in predicting ovarian response but has unfavorable value in predicting clinical pregnancy in GnRH antagonist protocol.Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years.Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.Occult Form of Premature Ovarian Insufficiency in Women with Infertility and Oligomenorrhea as Assessed by Poor Ovarian Response Criteria.Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis.Counting ovarian antral follicles by ultrasound: a practical guide.Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes.Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.Urinary phthalate metabolites in relation to serum anti-Müllerian hormone and inhibin B levels among women from a fertility center: a retrospective analysis.Relationship between anti-Müllerian hormone and antral follicle count across the menstrual cycle using the Beckman Coulter Access assay in comparison with Gen II manual assay.Double Stimulation in the Same Ovarian Cycle (DuoStim) to Maximize the Number of Oocytes Retrieved From Poor Prognosis Patients: A Multicenter Experience and SWOT Analysis.Fertility Preservation: Current and Future Perspectives for Oncologic Patients at Risk for Iatrogenic Premature Ovarian InsufficiencyDefining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria-The Why
P2860
Q28275450-87621C02-0F55-4E2F-A3CB-0141496F5F37Q28392743-3EF31C00-49BB-4238-8A8A-BF4D18602172Q36030666-C476C2E2-6AD7-463C-B997-517CE097A2ABQ36192094-7B00BFE9-B96B-47F7-8434-236D9C430813Q36444589-F25DB133-8B61-48EC-9960-EA93AFD96A6AQ36476164-5284D11C-8B0B-4C56-A045-39EE719B3931Q36584093-CB51AA8B-4DE5-4905-8318-B9EB1DEC52B5Q37593698-9A4CC4F2-C948-458A-B03A-6BC793B712EDQ37605344-06EA58D4-58F6-4003-9FFD-F4C72338316BQ38602025-744B9283-BB24-4B3A-93D3-3629ED33BC00Q38722378-8EF7E7A5-8342-472E-A24F-7837E883000DQ39067260-BCE75DB1-0C64-463C-AD20-4CF6DB1281E8Q40161541-84CCC6D2-AC5A-42B6-B4B2-4AA124EBEA2DQ40603713-C2385298-53AB-49FC-9C77-98191F319CDFQ40860461-4C3D23DB-C25C-42AE-9E99-4EDF3C345969Q46716306-24153AD3-6EEA-475B-9BA6-DEC7DC1597AAQ47221797-D960F986-63A6-49E8-AF3D-A2BABCCD86A1Q47369122-CDAC11FA-DBF6-40A3-B99E-DA63A38FA9E4Q47871435-DF6A7D87-E7CB-43C9-8427-0FC2AE4967C3Q48505409-D8093A19-B623-4D02-B03C-B3051022EDA5Q48605923-14D04051-36CB-410E-88D5-77EA65344676Q50300877-3A98A06F-77EB-4F75-9C1F-E571FD289631Q50531897-4E7DC7E1-D45D-4596-B980-32217683F6BCQ55428711-5775029F-BCBD-4E83-AD65-35AFEC8DF77EQ57176379-4156FAA6-0363-47FC-BA42-68D404E70043Q58769667-13E120D4-31A6-4A6B-A7F4-F6C5B457AB72
P2860
Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Technical and performance char ...... iomarkers of ovarian response.
@en
type
label
Technical and performance char ...... iomarkers of ovarian response.
@en
prefLabel
Technical and performance char ...... iomarkers of ovarian response.
@en
P2093
P2860
P356
P1476
Technical and performance char ...... iomarkers of ovarian response.
@en
P2093
Richard A Anderson
Scott M Nelson
Stamatina Iliodromiti
P2860
P304
P356
10.1093/HUMUPD/DMU062
P577
2014-12-08T00:00:00Z